⚠ Cheaper Rivals Will Eventually ComeModerate threat

Eli Lilly (LLY) — threat to the moat

Extraordinary profits are a magnet for competition and, on the patent's date, for copies.

The incretin market is so large and so profitable that it is certain to attract not just Novo but a widening field of competitors and, in time, cheaper alternatives — and the very size that makes it a generational opportunity guarantees ferocious efforts to grab a share of it. A wave of next-generation drugs from many companies is in development, biosimilar and generic competition will eventually arrive as patents age, and compounded and copycat versions have already appeared at the market's edges. Extraordinary profits are a magnet for competition.

Price effect on revenue outside the U.S. (%)-4%20230%20240%2025-31%H1 26-36%Q2 26Forms 10-K FY2023-FY2025 and 10-Q June 2026
Cheaper competition arrived first abroad, as price cuts to win volume.

The danger unfolds over years but is inexorable. As more branded rivals enter, pricing pressure builds and share fragments; as patents eventually expire, cheaper copies erode the franchise; and payers, straining under the cost of a drug this widely used, actively encourage lower-priced alternatives. The market may remain enormous, but Lilly's slice of it, and the price it can charge for that slice, will face steady competitive erosion as the field crowds and the drugs age toward their cliffs.

Lilly's strategy — stay first and best, keep innovating the next generation, and widen the market faster than rivals take share — is the right response, and a market growing this fast can accommodate several winners for a long time. But an owner should recognize that today's near-duopoly and premium pricing are features of an early, supply-constrained market, that competition and cheaper alternatives are coming as surely as night follows day, and that the incretin franchise's spectacular current economics — $49.5 billion over the twelve months to June 202612 — will, over time, be competed toward something more ordinary.

References
  1. ReportedBut an owner should recognize that today's near-duopoly and premium pricing are features of an early, supply-constrained market, that competition and cheaper alternatives are coming as surely as night follows day, and that the incretin franchise's spectacular current economics — $49.5 billion over the twelve months to June 2026 — will, over time, be competed toward something more ordinary.
    Eli Lilly Form 10-Q, quarter ended 30 June 2026 - revenue $22,974M (+48%): Mounjaro $9,943M (U.S. $4,791M, outside $5,152M), Zepbound $4,928M, Jardiance $1,232M, Trulicity $1,219M, Verzenio $1,474M; oncology $2,570M, immunology $1,417M, neuroscience $429M; volume +60% and price -13% (U.S. +37%/-3%, outside +113%/-36%); gross margin 85.8% (84.3%); R&D $3,819M; MS&A $3,430M; acquired IPR&D $2,776M; special charges $703M; tax rate 23.3% (16.5%); net income $7,095M; diluted EPS $7.94; H1 capital expenditure $5,259M and operating cash flow $16,023M — Q2 2026 · publ. August 2026 · source ↗
  2. Moat Explorer calcBut an owner should recognize that today's near-duopoly and premium pricing are features of an early, supply-constrained market, that competition and cheaper alternatives are coming as surely as night follows day, and that the incretin franchise's spectacular current economics — $49.5 billion over the twelve months to June 2026 — will, over time, be competed toward something more ordinary.
    Moat Explorer calculation from Lilly's Forms 10-K FY2021-FY2025 and the Q2 2026 10-Q: tirzepatide (Mounjaro + Zepbound) $36,507M in 2025, $14,871M in Q2 2026 ($8,580M), trailing twelve months $49,466M; trailing revenue $79,666M; margins and shares as stated — 2021 to Q2 2026 · publ. 2026-09-23 · source ↗
Sources
Generated September 23, 2026